Nomura Asset Management Co. Ltd. reduced its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 28.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 265,064 shares of the company’s stock after selling 107,700 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Teva Pharmaceutical Industries were worth $5,023,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Linden Advisors LP purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at approximately $3,790,000. Triarii Capital Management LP purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at approximately $3,790,000. Portland Hill Asset Management Ltd grew its holdings in Teva Pharmaceutical Industries by 27.8% during the 4th quarter. Portland Hill Asset Management Ltd now owns 39,947 shares of the company’s stock valued at $763,000 after buying an additional 8,690 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec grew its holdings in Teva Pharmaceutical Industries by 1,498.9% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 328,228 shares of the company’s stock valued at $6,220,000 after buying an additional 307,700 shares in the last quarter. Finally, MML Investors Services LLC grew its holdings in Teva Pharmaceutical Industries by 13.8% during the 4th quarter. MML Investors Services LLC now owns 104,517 shares of the company’s stock valued at $1,981,000 after buying an additional 12,671 shares in the last quarter. 58.22% of the stock is owned by institutional investors and hedge funds.
TEVA has been the subject of a number of research analyst reports. Goldman Sachs Group increased their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, January 11th. Morgan Stanley upgraded Teva Pharmaceutical Industries from an “underweight” rating to an “equal weight” rating and set a $18.00 target price for the company in a research report on Friday, December 15th. Royal Bank of Canada set a $11.00 target price on Teva Pharmaceutical Industries and gave the company a “sell” rating in a research report on Wednesday, November 29th. Cantor Fitzgerald set a $10.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday, December 14th. Finally, Susquehanna Bancshares reiterated a “positive” rating and set a $24.00 target price (up from $22.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, January 25th. Ten analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eight have assigned a buy rating to the stock. Teva Pharmaceutical Industries presently has a consensus rating of “Hold” and a consensus price target of $20.88.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, February 8th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The business had revenue of $5.46 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same period last year, the company earned $1.38 earnings per share. The business’s revenue for the quarter was down 15.9% compared to the same quarter last year. equities research analysts predict that Teva Pharmaceutical Industries Ltd will post 2.31 EPS for the current year.
In other news, EVP Mark Sabag sold 5,050 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $19.68, for a total transaction of $99,384.00. Following the completion of the sale, the executive vice president now directly owns 44,517 shares in the company, valued at $876,094.56. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 7,636 shares of company stock valued at $149,390. Corporate insiders own 7.10% of the company’s stock.
WARNING: This story was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3257489/teva-pharmaceutical-industries-ltd-teva-shares-sold-by-nomura-asset-management-co-ltd.html.
Teva Pharmaceutical Industries Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.